Medtronic is on track to raise its quarterly dividend for the 48th straight year, a milestone that would extend its status as one of the medical‐technology sector’s most reliable income generators. The board is expected to approve an increase in the payout later this quarter, marking nearly half a century of uninterrupted dividend growth. This consistency underscores Medtronic’s commitment to returning capital to shareholders even as it invests heavily in research, product development and selective acquisitions to sustain long‐term growth.

Two of Medtronic’s highest‐momentum businesses are its Pulsed Field Ablation (PFA) and Symplicity renal denervation franchises. PFA catheters, which deliver ultra‐rapid electrical pulses to treat atrial fibrillation, have seen adoption in over 3,200 procedures since launch, generating more than $150 million in revenue last year. The Symplicity system for treatment‐resistant hypertension, approved in Europe and under review by the FDA, contributed approximately $90 million in sales in 2025 and is on track for mid‐teens percentage growth as reimbursement expands.

Medtronic maintains an S&P credit rating of A with a stable outlook, reflecting its diversified revenue base and disciplined capital allocation framework. At the end of fiscal Q2, net debt stood at $21.4 billion against $13.2 billion in cash and equivalents, yielding a net leverage ratio of 2.1x EBITDA. Management has stated that it targets a leverage range of 2.0x–2.5x, leaving room for bolt-on acquisitions while protecting the dividend through economic cycles.

Analysts project mid-to-high single‐digit annual revenue growth over the next three years, with operating margins expanding by 50–75 basis points annually as cost‐synergy programs and productivity initiatives take full effect. Free cash flow is forecast to exceed $8 billion in fiscal 2026, supporting continued dividend raises, share repurchases of up to $3 billion per year and incremental strategic investments in areas such as next-generation neurostimulation and robotics. For yield‐seeking investors, Medtronic’s combination of consistent payout growth and exposure to secular trends in structural heart, diabetes care and minimally invasive therapies positions it as a core holding in diversified portfolios.